EUROBIO SCIENTIFIC MAKES A MINORITY INVESTMENT IN USENSE,
A START-UP DEVELOPPING A MOBILE IN VITRO MEDICAL DEVICE
FOR URIANALYSIS
With this investment, the Group strengthens its offer in point of care medical biology and positions itself in the digitalization of diagnostics
Using a proprietary blend of miniaturized technologies and artificial intelligence, Usense’s connected in vitro medical device can perform urinalysis with results obtained in seconds. The medical device is lightweight and portable, which allows it to be used as close as possible to patients, where the information is necessary for medical diagnosis. The company plans to start marketing the device in 2022.
A key investment for the dynamics of the
This investment fits directly with
« We were impressed with the patented technologies implemented in Usense's solution, with an accuracy confirmed by real-life testing. This investment allows our Group to immediately set foot in the future of diagnostics.» adds
« We are very proud of
Next financial meeting
2021 FY revenues:
Disclaimer
This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition,
About Usense
Usense is a MedTech offering a breakthrough technology in the field of point of care Medical Biology. With just one click, Usense's solution can measure most of the parameters usually analyzed in the urine by medical biology laboratories. By capitalizing on artificial intelligence and machine learning, this solution makes it possible to detect the presence of many biomarkers, thereby facilitating early diagnosis, control of pathologies and, more generally, monitoring of patients health status. It also helps to make the right decisions in an emergency context.
Contact
Guillaume Lemetais, President of Usense
glemetais@usense.healthcare
About
For more information, please visit : www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP
Contacts |
Group Tel. +33(0) 1 69 79 64 80 | Calyptus Investors relations Tel. +33(1) 53 65 68 68 eurobio-scientific@calyptus.net |
Attachment
- 211123_Eurobio_Usense_EN
© OMX, source